Psychosis Clinical Trial
Official title:
Manualized Group Cognitive-behavioral Therapy for Social Anxiety in First Episode Psychosis: A Randomized Controlled Trial
Verified date | October 2022 |
Source | Douglas Mental Health University Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Social anxiety represents one of the most prevalent comorbid conditions in schizophrenia and related psychosis. Schizophrenia patients with comorbid social anxiety often exhibit impaired social functioning, an increased risk for relapse, and higher rates of suicide. Social anxiety is a treatable condition but has, in the context of psychosis, received only scant attention thus far. There is strong evidence that cognitive-behavioral therapy (CBT) for the treatment of social anxiety is very effective, whether it is delivered individually or in a group setting, and studies have shown that a group setting is more effective than individual therapy. Providing a CBT intervention for social anxiety represents an effective way to empower people with this illness. The investigators have conducted a preliminary study using an uncontrolled design to assess feasibility and initial benefits of a new manualized group CBT intervention for social anxiety specifically adapted for people with psychosis. The investigators observed a significant reduction in social anxiety symptoms across three groups of first episode psychosis (FEP) participants (n=29) following completion of this 13-week intervention, and observed large effect sizes confirming a significant positive influence of this intervention. The investigators now propose to conduct a randomized controlled trial to fully assess the efficacy of this intervention. The main objective of this research proposal is to contrast the impact of a CBT intervention for the treatment of social anxiety in first episode psychosis with another control condition involving computer assisted cognitive remediation therapy (CACRT). Both interventions will be offered in a group setting, and will therefore have the exact same parameters. A secondary objective of this study is to examine the impact of reduced social anxiety on measures of clinical and functional outcome. For this trial, 120 patients with recent onset psychotic disorder (defined as within 5 years from their first episode of psychosis) and with social anxiety will be clinically assessed. These participants will be recruited from five different first episode psychosis programs in the Montreal area and referred by their treatment team. They will then be randomly assigned to either the CBT or CACRT conditions. Both interventions will involve 13 weekly group sessions. At the end of group interventions and at two follow-ups (3-month & 6-month), the presence and severity of social anxiety symptoms will be assessed. It is hypothesized that compared to the CACRT group, individuals receiving the CBT intervention will show a reduction in symptoms associated with social anxiety (as determined with multiple self-report and clinician rated measures). This effect will be maintained at follow-ups. In addition, the investigators also hypothesize that the CBT group will show better clinical outcome, defined as the length of symptomatic remission at follow-ups. For functional outcome, they will show significant improvement on a self-report measure a clinician-rated measure of recovery. This study will be one of the first to specifically target social anxiety in people with psychosis using a psychosocial intervention. As such, it will tackle an important problem that is interfering with recovery and with the actualization of functional roles.
Status | Completed |
Enrollment | 105 |
Est. completion date | December 19, 2019 |
Est. primary completion date | December 19, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 35 Years |
Eligibility | Inclusion Criteria: - diagnosis of a psychotic disorder (as determined by the SCID and consensus meeting between two research psychiatrists); - ability to read and write English or French at an intermediate level (Education > 8 years); - social anxiety scores above predetermined cut-offs on at least one of the three social anxiety measures (34 for the SIAS, above 19 for the SPIN and above 20 for the BSPS); and the presence of observable clinical symptoms supporting the diagnosis of a social anxiety disorder on Axis I and determined with the SCID social phobia module. Exclusion Criteria: - currently clinically unstable, defined as the presence of positive symptoms that are moderate to severe on the SAPS rating scale; - IQ<70; - currently hospitalized or hospitalized at the time of recruitment; - a change in medication within the past 6 weeks; presence of a current episode of major depression (evidenced by Calgary Depression Scale (CDS) rating score of 8 or greater); - current diagnosis of substance dependence (but a diagnosis of substance abuse is not an exclusion criterion); - lifetime history of a neurological condition; - history of mental retardation or autism spectrum disorders. |
Country | Name | City | State |
---|---|---|---|
Canada | Douglas Mental Health University Institute | Verdun | Quebec |
Lead Sponsor | Collaborator |
---|---|
Douglas Mental Health University Institute | Canadian Institutes of Health Research (CIHR) |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Social anxiety symptoms as measured by the Social Interaction Anxiety Scale (SIAS) | Participants:
120 participants receiving treatment for a FEP with social anxiety symptoms aged 18-35 will be recruited in Montreal from five FEP clinics affiliated with McGill University or Université de Montréal. Half of these participants will receive CBT, the other half CACRT. Assessment: As part of a thorough clinical assessment, symptoms of social anxiety will be assessed for each participant at intake, at the end of the therapy, and 3 and 6 months after the therapy. Change in symptom severity will be evaluated over time. Assessment will be conducted by a by a trained bilingual rater who will be blind to treatment. Unit of measure: The unit of measure used is the Social Interaction Anxiety Scale (SIAS). The SIAS is a 20-item scale which measures anxiety in interpersonal encounters. |
pre-treatment, 1 week, three and six-month follow-up | |
Primary | Social anxiety symptoms as measured by the Social Phobia Inventory (SPIN) | Participants:
120 participants receiving treatment for a FEP with social anxiety symptoms aged 18-35 will be recruited in Montreal from five FEP clinics affiliated with McGill University or Université de Montréal. Half of these participants will receive CBT, the other half CACRT. Assessment: As part of a thorough clinical assessment, symptoms of social anxiety will be assessed for each participant at intake, at the end of the therapy, and 3 and 6 months after the therapy. Change in symptom severity will be evaluated over time. Assessment will be conducted by a by a trained bilingual rater who will be blind to treatment. The unit of measure used is the Social Phobia Inventory (SPIN). The SPIN is a 17-item scale assessing multiple dimensions of social anxiety including fear, avoidance and physiological discomfort. |
pre-treatment, 1 week, three and six-month follow-up | |
Primary | Social anxiety symptoms as measured by the the Brief Social Phobia Scale (BSPS) | Participants:
120 participants receiving treatment for a FEP with social anxiety symptoms aged 18-35 will be recruited in Montreal from five FEP clinics affiliated with McGill University or Université de Montréal. Half of these participants will receive CBT, the other half CACRT. Assessment: As part of a thorough clinical assessment, symptoms of social anxiety will be assessed for each participant at intake, at the end of the therapy, and 3 and 6 months after the therapy. Change in symptom severity will be evaluated over time. Assessment will be conducted by a by a trained bilingual rater who will be blind to treatment. Unit of measure: The unit of measure used is the Brief Social Phobia Scale (BSPS). The BSPS is an 11-item clinician-rated assessment scale developed by Davidson which specifically measures fear, avoidance and autonomic physiological responses that are usually associated with most common social situations. |
pre-treatment, 1 week, three and six-month follow-up | |
Secondary | Psychosis Symptoms Remission as measured by the Scale for Assessment of Positive Symptoms (SAPS) and Negative Symptoms (SANS) | Participants:
120 participants receiving treatment for a FEP with social anxiety symptoms aged 18-35 will be recruited in Montreal from five FEP clinics affiliated with McGill University or Université de Montréal. Half of these participants will receive CBT, the other half CACRT. Assessment: As part of a thorough clinical assessment, symptoms of social anxiety will be assessed for each participant at intake, at the end of the therapy, and 3 and 6 months after the therapy. Psychosis symptom remission will be evaluated over time. Assessment will be conducted by a by a trained bilingual rater who will be blind to treatment. Unit of measure: The unit of measure used is the Scale for Assessment of Positive Symptoms (SAPS) and Negative Symptoms (SANS). The SAPS and SANS is a 59-item scale assessing multiple categories of positive and negative symptoms. |
pre-treatment, 1 week, three and six-month follow-up | |
Secondary | Functional outcome as measured by the Recovery Assessment Scale (RAS) | Participants:
120 participants receiving treatment for a FEP with social anxiety symptoms aged 18-35 will be recruited in Montreal from five FEP clinics affiliated with McGill University or Université de Montréal. Half of these participants will receive CBT, the other half CACRT. Assessment: As part of a thorough clinical assessment, symptoms of social anxiety will be assessed for each participant at intake, at the end of the therapy, and 3 and 6 months after the therapy. Functional recovery will be evaluated over time. Assessment will be conducted by a by a trained bilingual rater who will be blind to treatment. Unit of measure: The unit of measure used is the Recovery Assessment Scale (RAS). The RAS is a 41-item self-report measure examining multiple dimensions of functional recovery as perceived by the patient him/herself. |
pre-treatment, 1 week, three and six-month follow-up | |
Secondary | Functional outcome as measured by the Social and Occupational Functioning Scale (SOFAS). | Participants:
120 participants receiving treatment for a FEP with social anxiety symptoms aged 18-35 will be recruited in Montreal from five FEP clinics affiliated with McGill University or Université de Montréal. Half of these participants will receive CBT, the other half CACRT. Assessment: As part of a thorough clinical assessment, symptoms of social anxiety will be assessed for each participant at intake, at the end of the therapy, and 3 and 6 months after the therapy. Functional recovery will be evaluated over time. Assessment will be conducted by a by a trained bilingual rater who will be blind to treatment. Unit of measure: The unit of measure used is the the Social and Occupational Functioning Scale (SOFAS). The SOFAS is used to evaluate the individual's level of social and occupational functioning independent of the overall severity of psychiatric symptoms. |
pre-treatment, 1 week, three and six-month follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04929938 -
Application of UP for Transdiagnostic Treatment of Emotional Disorders for UHR for Psychosis Patients
|
N/A | |
Recruiting |
NCT05863572 -
Strengthening Care in Collaboration With People With Lived Experience of Psychosis in Uganda
|
N/A | |
Completed |
NCT04277585 -
Improving Access to Early Psychosis Coordinated Specialty Care
|
N/A | |
Recruiting |
NCT06197048 -
Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Terminated |
NCT04404712 -
FAAH Availability in Psychiatric Disorders: A PET Study
|
Early Phase 1 | |
Recruiting |
NCT05769933 -
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
|
||
Recruiting |
NCT04298450 -
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
|
N/A | |
Not yet recruiting |
NCT05558332 -
Youth Nominated Support Team
|
N/A | |
Not yet recruiting |
NCT05358457 -
Pilot Study to Evaluate the Effectiveness of Online Familiar Metacognitive Training (MCTf)
|
N/A | |
Not yet recruiting |
NCT03807388 -
ReMindCare App for Patients From First Episode of Psychosis Unit.
|
N/A | |
Completed |
NCT02895269 -
COllaborative Shared Care to IMprove Psychosis Outcome
|
N/A | |
Recruiting |
NCT02622048 -
Understanding and Helping Families: Parents With Psychosis
|
N/A | |
Completed |
NCT02653729 -
Cbt for Psychosis and Affect on Psychosis Symptoms
|
Phase 2 | |
Completed |
NCT02733575 -
Compassion Focused Therapy for Distressing Experiences
|
N/A | |
Completed |
NCT02531243 -
Computer-Aided Learning for Managing Stress
|
N/A | |
Not yet recruiting |
NCT02244970 -
Mindfulness RCT for Early Psychosis
|
N/A | |
Enrolling by invitation |
NCT01364818 -
Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment
|
N/A | |
Withdrawn |
NCT00786318 -
Ziprasidone vs Standard Therapy for Agitated Patients in the ED
|
Phase 4 | |
Recruiting |
NCT00722163 -
A Randomized Controlled Trial of Individual Therapy for First Episode Psychosis
|
Phase 0 |